ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
38 announcements with these filters
Jubilant Pharmova Q4FY26 revenue grew 19% YoY to ₹2,290 Cr. FY26 revenue reached ₹8,280 Cr (up 14%) driven by CDMO Sterile Injectables and Radiopharma growth.
Jubilant Pharmova recommended a final dividend of ₹5 per equity share for 2026. The record date is set for July 24, 2026, awaiting shareholder approval.
Jubilant Pharmova's subsidiary received a Rs. 107.89 Crore income tax demand order. The company intends to appeal, anticipating no material financial impact post-adjudication.
Jubilant Pharmova reported FY26 revenue of ₹8,280 Crore, a 14% YoY increase. Growth was driven by the CDMO Sterile Injectables segment and expanded Ruby-Fill® installations.
Jubilant Pharmova approved the re-appointment of Mr. Priyavrat Bhartia and Mr. Arjun Shanker Bhartia for three-year terms. These appointments ensure leadership continuity for upcoming years.
Jubilant Pharmova appointed Ashish Mukkirwar as CFO effective May 23, 2026. He succeeds Arun Kumar Sharma, who transitions to an advisory role following his resignation.
Jubilant Pharmova Ltd reported revenue from operations of ₹2,290 Cr (+18.7% YoY) and net profit of ₹119.3 Cr (-21.2% YoY) for Q4 FY26.
Jubilant Pharmova reported audited FY26 financial results and recommended a 500% final dividend of ₹5 per share. Totaling ₹79.6 Crore, payment follows shareholder approval.